Industry News
Magnetic resonance network for Queensland
The University of Queensland is establishing the Queensland Nuclear Magnetic Resonance Network (QNN), placing UQ at the forefront of international research in structural biology, biodiscovery and animal neuroimaging.
[ + ]Mesoblast stem cell trial gets ethics approval
Adult stem cell specialist Mesoblast (ASX:MSB) has received ethics approval to commence its first human orthopaedic trial. [ + ]
Chemeq signs $1.4m sales order
Perth-based Chemeq (ASX:CMQ) has signed a new sales order for the shipment of CHEMEQ polymeric antimicrobial worth AUD$1.4 million over the next nine months. [ + ]
Narhex appoints new scientific advisory board
Narhex Life Sciences (ASX:NLS) has formed a new scientific advisory board, following Prof John Mills' appointment last week as managing director, replacing founder John Majewski, and the relocation of the company's head office to Melbourne. [ + ]
CathRx opens IPO for listing next month
Sydney medical device company CathRx has opened its initial public offering and aims to raise AUD$14 million before listing on the ASX in late October. [ + ]
New drug discovery facility for Melbourne
The privately funded Australian Cancer Research Foundation (ACRF) has awarded a grant of AUD$900,000 to Melbourne's St Vincent's Institute (SVI) to establish a rational drug discovery facility for cancer research. [ + ]
Biosignal woos potential customers in oil, gas
Sydney-based Biosignal (ASX:BOS) has piqued the interest of some major international oil and gas companies. [ + ]
Aussie biotech getting better at global partnering: report
The Australian biotechnology industry is showing new signs of maturity, evidenced by a substantial increase in international alliance activity, according to a new analysis by industry consultant Innovation Dynamics. [ + ]
GBC leads way in export success
GBC Scientific has recently completed a major shipment of atomic absorption spectrometers to India. The single order was for 58 instruments and a large volume of accessories and consumable items. GBC is an Australian manufacturer, with these instruments (and others) designed, developed and manufactured at the company's international head office in Dandenong, Victoria.
[ + ]Vaxine awarded $2.5m bioterrorism grant
Privately-held vaccine developer Vaxine and Flinders University have been awarded a grant of US$2.5 million over three years by the US National Institutes of Health (NIH) to develop vaccines that protect against bioterrorist attacks. [ + ]
Biota aims to raise $10m
Melbourne-based Biota Holdings (ASX:BTA) is aiming to raise more than AUD$10 million in a non-renounceable share offer to existing shareholders. [ + ]
Mesoblast to start commercial stem cell production
Melbourne-based Mesoblast (ASX:MSB) has signed a process development and manufacturing agreement with US life sciences company Cambrex Corporation (NYSE:CMB) for the large scale production of Mesoblast's adult stem cells. [ + ]
Local pharma firms to distribute Funhaler
Perth-based biomedical devices developer Visiomed Group (ASX:VSG) has successfully competed negotiations with three pharmaceutical wholesale distributors in Australia for the distribution of its Funhaler incentive asthma spacer into Australian pharmacies. [ + ]
Phosphagenics claims promising insulin results
Melbourne's Phosphagenics (ASX:POH) has successfully delivered insulin through the skin of animals using its patented transdermal drug delivery system TPM-01. [ + ]
Ventracor chalks up first revenues
Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial. [ + ]
